The Munich Medtech-Startup Symphera develops surgical systems for laparoscopic procedures that automate instrument changes and eliminate the need for manual instrument changes. At the touch of a button, surgeons can seamlessly switch between instruments, allowing them to fully focus on the surgical procedure. This simplifies the surgical workflow, reduces operating time, and improves patient care.
Symphera: Focus on product development & preclinical studies
According to the company, the newly raised funds will be used for product development and the conduct of initial preclinical studies in preparation for certification. These milestones are crucial for bringing Symphera's technology closer to market readiness, with the goal of transforming laparoscopic surgery and sustainably improving patient care.
Jan Engels, Investment Manager at HTGF, says:
"Symphera's surgical tool addresses the entire spectrum of laparoscopy, from improving standard workflows to robot-assisted applications, making Symphera a strong venture case in a highly exciting area."
“Exciting investment case in the medtech sector”
Monika Steger, Managing Director of Bavaria Capital, continues:
"With its all-in-one instrument, the Symphera team has developed a way to make shorter surgeries possible. The existing Symphera prototype convinced us and makes Symphera an exciting investment case for us in the medtech sector."
And Christian Leikert, Managing Partner of Carma Fund, adds:
"We are impressed by Symphera's founders and the potential to revolutionize laparoscopic surgery with an intuitive solution. The potential future application in robotic and robot-assisted surgery offers the company significant additional opportunities."
